High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Inclusion Criteria

• Subject or subject's legally acceptable representative has provided informed consent.
• Histologically confirmed diagnosis of locally advanced soft tissue sarcoma of extremity, trunk or retroperitoneum that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate
• Including metastatic (stage IV) disease for which radiotherapy and surgical resection of the primary tumor are indicated.
• Patients with locally recurrent sarcoma after surgery alone are eligible for enrollment if other inclusion criteria are met.
• Patients do not have histologic subtypes: GIST, Desmoid, Ewing sarcoma, bone sarcomas and Kaposi sarcoma.
• Age ≥18 years.
• Patients with a history of non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate cancer can be enrolled.
• ECOG performance status /= 5 cm in the longest diameter as measured by CT scan or MRI for which radiation is feasible and indicated.

Exclusion Criteria

• Inadequate organ function within 21 days of Day 1 of study as defined by:
• Hemoglobin /= 1.5 × ULN. Subjects with direct bilirubin 1.5 X ULN will not be excluded.
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN
• Alkaline phosphatase > 2.5 × ULN
• PT (or INR) and PTT (or aPTT) >/= 1.5 × ULN
• Creatinine > 2.0 × ULN
• G6PD (glucose-6-phosphate dehydrogenase) deficiency.
• Prior history of symptomatic oxalate kidney stones within the last year.
• Prior radiation therapy in excess of 20 Gy to the site of the current diagnosis of sarcoma. No overlap with prior radiation fields in excess of 20 Gy is allowed.
• Prior history of receiving pharmacological ascorbate.
• Patients actively receiving insulin therapy and needing daily fingerstick for glucose monitoring.
• Concurrent, clinically significant, active malignancies within two years of study enrollment.
• Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment.
• Female subjects of childbearing potential or male subjects who are unwilling to use 2 highly effective methods of contraception during study treatment and through 3 months after the last dose of study treatment.
• Currently receiving treatment in another invasive investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).
• Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs.
• Known CNS disease, except for treated brain metastasis: Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to ascorbate.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Known HIV-positive and hepatitis B & C individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.
• Pati